What is the recommended management, including prophylaxis and follow‑up testing, for a person exposed to blood or bodily fluids from a hepatitis B surface antigen (HBsAg)‑positive individual?

Management of HBsAg-Positive Exposure

For any person exposed to blood or body fluids from an HBsAg-positive source, administer hepatitis B immune globulin (HBIG) 0.06 mL/kg intramuscularly and initiate or complete the hepatitis B vaccine series immediately—preferably within 24 hours of exposure—unless the exposed person has documented protective immunity (anti-HBs ≥10 mIU/mL). 1, 2

Immediate Actions (Within 24 Hours)

Source Confirmation

• Confirm the source patient's HBsAg-positive status immediately through laboratory testing 1
• Document the exposure type (percutaneous, mucosal, sexual contact, or other blood/body fluid contact) 1

Assess Vaccination Status of Exposed Person

The management algorithm depends entirely on the exposed person's hepatitis B vaccination history and documented immune response:

Unvaccinated or Incompletely Vaccinated Persons

• Give HBIG 0.06 mL/kg IM immediately (preferably within 24 hours, but effective up to 7 days post-percutaneous exposure) 1, 2
• Simultaneously administer the first dose of hepatitis B vaccine at a separate anatomic site (e.g., opposite deltoid) 1
• Complete the 3-dose vaccine series at 0,1, and 6 months 1
• Perform anti-HBs testing 4–6 months after HBIG administration (not 1–2 months, to avoid detecting passively transferred antibodies from HBIG) 1

Previously Vaccinated—Documented Immunity (Anti-HBs ≥10 mIU/mL)

• No treatment required—no HBIG, no vaccine booster, no testing 1
• Documented immunity provides complete protection regardless of time since vaccination 1

Previously Vaccinated—Immunity Status Unknown

• Immediately give HBIG 0.06 mL/kg IM plus one hepatitis B vaccine booster dose at a separate site, without waiting for serologic results 1
• This approach prioritizes rapid prophylaxis over delayed testing, because giving HBIG to an immune person causes no harm, while withholding it from a non-immune person risks infection 3
• Draw blood at the time of exposure for later anti-HBs testing if desired, but do not delay treatment 3

Previously Vaccinated—Documented Non-Responder (Anti-HBs <10 mIU/mL After Two Complete 3-Dose Series)

• Give HBIG 0.06 mL/kg IM immediately 1
• Give a second dose of HBIG one month later (total of two doses) 1, 2
• Do not administer additional vaccine doses—six total doses is the maximum recommended 1, 4
• Counsel the person that they remain susceptible and will require HBIG for any future HBsAg-positive exposures 1, 4

Critical Timing Considerations

HBIG Effectiveness Window

• HBIG effectiveness declines markedly after 7 days for percutaneous exposures (e.g., needlestick, bite) 1, 3, 2
• HBIG effectiveness declines markedly after 14 days for sexual exposures 1, 3
• The 24-hour target is optimal, but do not withhold HBIG if 48–72 hours have passed—it remains protective through the first week 3
• Beyond 7 days (percutaneous) or 14 days (sexual), HBIG may provide no meaningful benefit, but still initiate the vaccine series 3

Administration Details

HBIG Dosing and Route

• Dose: 0.06 mL/kg body weight, administered intramuscularly (typically deltoid muscle) 1, 2
• Administer HBIG and hepatitis B vaccine at separate anatomic sites (e.g., different arms) to ensure optimal immune response 1

Vaccine Dosing

• Adults: 20 μg (1.0 mL) IM 2
• Infants and children <10 years: 10 μg (0.5 mL) IM 2

Follow-Up Testing

Timing of Serologic Testing

• If HBIG was given: Test anti-HBs 4–6 months after HBIG administration to avoid detecting passive antibodies 1, 3
• If HBIG was not given: Test anti-HBs 1–2 months after completing the vaccine series 1
• Protective immunity is defined as anti-HBs ≥10 mIU/mL 1

For Persons Who Received Vaccine Without Prior Testing

• If anti-HBs <10 mIU/mL after the first complete series, administer a second complete 3-dose series 1, 4
• Retest 1–2 months after the third dose of the second series 1, 4
• If still <10 mIU/mL after six total doses, test for HBsAg and anti-HBc to rule out chronic HBV infection 1, 4

Common Pitfalls and How to Avoid Them

Pitfall 1: Delaying Treatment to Await Serologic Results

• Solution: Administer HBIG and vaccine immediately based on vaccination history alone; do not wait for anti-HBs results 3
• The risk of not treating a non-immune person far outweighs the cost of treating someone who may already be protected 3

Pitfall 2: Withholding HBIG After 24 Hours

• Solution: The 24-hour window is a target for optimal efficacy, not an absolute cutoff—HBIG remains effective up to 7 days post-percutaneous exposure 3, 2

Pitfall 3: Testing Anti-HBs Too Soon After HBIG

• Solution: Wait 4–6 months after HBIG before testing anti-HBs to avoid false-positive results from passively transferred antibodies 1, 3

Pitfall 4: Assuming Immunity Without Documentation

• Solution: Accept only written, dated records of vaccination and serologic testing as proof of immunity 1
• Verbal history or recalled vaccination is insufficient—treat as unvaccinated if documentation is unavailable 1

Pitfall 5: Restarting the Vaccine Series If Interrupted

• Solution: If the vaccine series is interrupted, simply administer the next dose as soon as possible—do not restart the series 4
• Previously administered doses remain valid 4

Pitfall 6: Giving Unnecessary Boosters to Immune Persons

• Solution: Persons with documented anti-HBs ≥10 mIU/mL require no further treatment, regardless of time since vaccination or current antibody levels 1
• Immune memory persists even when antibody levels decline below detectable thresholds 4

Special Populations

Healthcare Personnel

• All HCP with reasonably anticipated blood or body fluid exposure should have documented vaccination and postvaccination serologic testing on file before any exposure occurs 1, 5
• This pre-exposure documentation streamlines post-exposure management 5

Hemodialysis Patients and Immunocompromised Persons

• These populations may require annual anti-HBs monitoring and boosters when levels fall below 10 mIU/mL, even without exposure 4
• Modified dosing regimens (doubled antigen doses) may improve response rates 4

Exposure to Source with Unknown HBsAg Status

If the source's HBsAg status cannot be determined:

• Unvaccinated or incompletely vaccinated persons: Initiate the hepatitis B vaccine series immediately (first dose within 24 hours); do not give HBIG unless the source is later confirmed high-risk 1
• Previously vaccinated persons with documented immunity: No treatment required 1
• Previously vaccinated persons without documented immunity: Complete the vaccine series; no HBIG unless source is confirmed HBsAg-positive 1